Liquid Biopsy Market Size & Share 2026-2035

Liquid Biopsy Market Size

The global liquid biopsy market was valued at USD 6.3 billion in 2025 and is projected to grow from USD 7.1 billion in 2026 to USD 19.9 billion by 2035, expanding at a CAGR of 12.1%, according to the latest report published by Global Market Insights Inc. This substantial growth is driven by several key factors, including continuous technological advancements in cancer diagnostics, increasing preference for non-invasive disease diagnosis and growing prevalence of cancer worldwide.

Liquid biopsy is a minimally invasive diagnostic test that detects cancer-related biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or other molecules, in body fluids like blood. It helps in the early detection, monitoring, and treatment selection of cancer without the need for a surgical tissue biopsy. Liquid biopsies can also be used to track disease progression and identify treatment resistance over time.

Leading companies in the market include Guardant Health, Thermo Fisher Scientific Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., and QIAGEN N.V. These companies are strengthening their market presence by advancing liquid biopsy technologies, expanding their molecular diagnostics portfolios, and enhancing comprehensive genomic profiling capabilities. They are focused on improving biomarker detection sensitivity, increasing the accuracy of cancer diagnostics, and broadening the clinical applications of liquid biopsy across cancer screening, treatment selection, and disease monitoring.

The rising global burden of cancer is a major driver of growth in the liquid biopsy market. According to the American Cancer Society, approximately 19 million new cancer cases and 10 million cancer-related deaths occur worldwide each year, excluding non-melanoma skin cancer. Furthermore, the organization estimates that, without significant intervention, cancer incidence could surpass 33 million cases and mortality could reach 18 million deaths annually by 2050, largely due to population growth and aging. As cancer prevalence increases, healthcare systems are placing greater emphasis on early detection, continuous disease monitoring, and personalized treatment strategies to improve patient outcomes. Liquid biopsy has emerged as a valuable diagnostic tool in this landscape because it offers a minimally invasive method for detecting and monitoring cancer through biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). The technology enables earlier diagnosis, real-time assessment of treatment response, and detection of disease recurrence, reducing the need for repeated tissue biopsies. Moreover, the high incidence of lung cancer the most commonly diagnosed cancer and the leading cause of cancer deaths globally, accounting for approximately 1.8 million deaths annually further supports the adoption of liquid biopsy solutions, particularly for precision oncology applications.

Additionally, the growing preference for non-invasive diagnostic methods is a significant driver of the liquid biopsy market. Traditional tissue biopsies often require surgical or needle-based procedures, which can be painful, carry procedural risks, and may not always be feasible, particularly for patients with hard-to-reach tumors or advanced-stage cancers. As healthcare providers and patients increasingly prioritize safer and more convenient diagnostic approaches, demand for liquid biopsy technologies continues to rise. Liquid biopsy offers a minimally invasive alternative by analyzing cancer-related biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles, from blood or other bodily fluids. This approach reduces patient discomfort, lowers the risk of complications, and allows for repeated sample collection over the course of treatment. The ability to perform serial testing enables clinicians to monitor disease progression, assess treatment effectiveness, and detect recurrence in real time. Additionally, advancements in molecular diagnostics and precision medicine are further accelerating the adoption of liquid biopsy, making it an increasingly preferred tool for early cancer detection and personalized disease management.
 

Liquid Biopsy Market Trends

• Continuous technological advancements in cancer diagnostics are emerging as a major trend in the market. Innovations in molecular testing, biomarker analysis, and genomic profiling are improving the accuracy and sensitivity of cancer detection, enabling clinicians to identify tumors at earlier stages and support personalized treatment strategies.
• The integration of advanced sequencing technologies and artificial intelligence into diagnostic workflows is enhancing the detection of low-abundance cancer biomarkers from blood samples. These developments are improving the reliability of liquid biopsy tests and expanding their use across multiple cancer types, supporting broader clinical adoption.
• For instance, Guardant Health's Guardant360 Liquid CDx combines genomic and epigenomic profiling from a single blood draw, enabling more comprehensive tumor analysis and improved circulating tumor DNA (ctDNA) detection. Such advancements help clinicians make more informed treatment decisions and strengthen the role of liquid biopsy in precision oncology.
• Furthermore, advancements in personalized monitoring technologies and next-generation sequencing (NGS) platforms are enabling real-time assessment of treatment response and early detection of cancer recurrence. These innovations are expanding the clinical applications of liquid biopsy beyond diagnosis, contributing significantly to market growth and the widespread adoption of minimally invasive cancer testing.

Liquid Biopsy Market Analysis

Based on the product, the liquid biopsy market is segmented into consumables, instruments, and services. The consumables segment is further sub-segmented into kits and reagents, and assay and panels. The consumables segment accounted for the highest market share of 58.9% in 2025.

• The segment's dominance is attributed to the recurring demand for products used throughout the testing workflow, including sample preparation, nucleic acid extraction, biomarker detection, and molecular analysis. Continuous utilization of consumables across research laboratories, diagnostic centers, and hospitals supports steady revenue generation.
• The segment encompasses kits and reagents as well as assays and panels, which are essential for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other cancer biomarkers. Growing adoption of liquid biopsy for early cancer detection, therapy selection, and treatment monitoring continues to drive the demand for advanced and specialized consumable products.
• The instruments segment accounted for USD 1.6 billion in 2025 and is projected to expand at a CAGR of 11.7% from 2026 to 2035. The instruments segment comprises platforms and systems used for sample processing, sequencing, polymerase chain reaction (PCR), and biomarker analysis in liquid biopsy applications. These instruments play a critical role in ensuring accurate detection and characterization of cancer-related biomarkers, supporting clinical and research applications.
• Technological advancements in next-generation sequencing (NGS), digital PCR, and automated laboratory systems are enhancing the efficiency and sensitivity of liquid biopsy testing. The increasing focus on precision oncology and molecular diagnostics is encouraging healthcare facilities and research institutions to invest in sophisticated analytical instruments.
• The services segment accounted for USD 991.6 million in 2025 and is projected to expand at a CAGR of 12.5% from 2026 to 2035. The services segment includes laboratory testing services, bioinformatics support, data interpretation, and specialized diagnostic services associated with liquid biopsy procedures. Service providers assist healthcare organizations in managing complex genomic analyses and generating clinically actionable insights from liquid biopsy data. The expansion of outsourced diagnostic testing and growing demand for comprehensive cancer profiling are supporting the adoption of service-based offerings.
• Additionally, increasing collaboration between healthcare providers, diagnostic laboratories, and biotechnology companies is facilitating broader access to liquid biopsy testing and related analytical services.

Based on biomarkers, the liquid biopsy market is segmented into circulating tumor cells (CTC), circulating tumor DNA, cell-free DNA, extracellular vesicles, and other biomarkers. The circulating tumor cells segment held the largest share of 38.5% in 2025.

• The segment's strong position is attributed to the clinical significance of CTCs as cancer cells shed from primary or metastatic tumors into the bloodstream. Their detection and analysis provide valuable information regarding tumor progression, metastasis, and treatment response, making them an important biomarker in cancer management.
• Growing adoption of CTC-based testing in oncology research and clinical practice is contributing to market expansion. CTC analysis supports early cancer detection, prognosis assessment, therapy selection, and disease monitoring, helping clinicians make informed treatment decisions. Continuous advancements in cell isolation and detection technologies are further enhancing the accuracy and clinical utility of CTC-based liquid biopsy solutions, thereby supporting overall market growth.
• The circulating tumor DNA segment accounted for USD 2 billion in 2025 and is projected to expand at a CAGR of 12.2% from 2026 to 2035. The circulating tumor DNA (ctDNA) segment comprises fragmented DNA released into the bloodstream by tumor cells. ctDNA analysis enables the identification of genetic mutations, molecular alterations, and treatment-resistant variants through a minimally invasive procedure, making it an increasingly important tool in precision oncology.
• The growing use of ctDNA for companion diagnostics, treatment monitoring, and recurrence detection is supporting segment growth. Advancements in next-generation sequencing (NGS) and digital PCR technologies have improved ctDNA detection sensitivity, allowing healthcare providers to utilize liquid biopsy for personalized cancer management and expanding the market's clinical applications.
• The cell-free DNA segment accounted for USD 1 billion in 2025 and is projected to expand at a CAGR of 12.6% from 2026 to 2035. The cell-free DNA (cfDNA) segment includes extracellular DNA fragments present in the bloodstream that originate from both normal and cancerous cells. Analysis of cfDNA provides valuable molecular information and serves as a foundation for various liquid biopsy applications, particularly in cancer diagnostics and monitoring.
• Increasing utilization of cfDNA-based testing for non-invasive disease assessment is driving demand across healthcare settings. The ability to obtain molecular insights from blood samples supports early diagnosis and longitudinal monitoring, contributing to broader adoption of liquid biopsy technologies and market growth.
• The extracellular vesicles segment accounted for USD 600.3 million in 2025 and is projected to expand at a CAGR of 13% from 2026 to 2035. The extracellular vesicles segment consists of membrane-bound particles released by cells that contain proteins, nucleic acids, and other bioactive molecules. These vesicles serve as important carriers of tumor-related information and offer a promising source of biomarkers for cancer diagnosis and monitoring.
• Growing research activities focused on extracellular vesicle characterization are expanding their potential applications in oncology. Their ability to provide comprehensive molecular information from readily accessible body fluids is enhancing interest in liquid biopsy-based diagnostics and supporting ongoing market development.

Based on the disease indication, the liquid biopsy market is segmented into cancer and non-cancer. Cancer is further segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and other applications. Similarly, the non-cancer segment is further segmented into non-invasive prenatal testing, organ transplantation, and infectious disease testing. The cancer segment accounted for the highest market share of 85.9% in 2025.

• Liquid biopsy has become an important component of precision oncology due to its ability to provide real-time insights into tumor genetics through blood-based testing.
• The widespread application of liquid biopsy across various cancer types, including lung, breast, colorectal, prostate, and liver cancer, continues to support market growth. Technology enables the detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other tumor-derived biomarkers, helping clinicians monitor treatment response, identify resistance mutations, and detect disease recurrence, thereby expanding adoption across oncology settings.
• The non cancer segment accounted for USD 892.4 million in 2025 and is projected to expand at a CAGR of 11.2% from 2026 to 2035. The non-cancer segment includes the use of liquid biopsy technologies for the diagnosis and monitoring of conditions beyond oncology, such as prenatal testing, organ transplant monitoring, infectious diseases, and genetic disorders. The ability to obtain molecular information from blood and other body fluids is supporting the development of non-invasive diagnostic approaches across multiple therapeutic areas.
• Increasing advancements in molecular diagnostics and biomarker analysis are expanding the clinical applications of liquid biopsy in non-cancer indications. Growing interest in early disease detection and personalized healthcare is encouraging the utilization of liquid biopsy-based testing, contributing to the segment's continued development and supporting overall market expansion.

Based on the clinical application, the liquid biopsy market is segmented into treatment monitoring, prognosis and recurrence monitoring, treatment selection, and diagnosis and screening. The treatment monitoring segment accounted for the highest market share and was valued at USD 2.5 billion in 2025.

• The growing adoption of liquid biopsy for monitoring therapeutic effectiveness and tracking molecular changes in cancer patients during treatment supports the segment's expansion. By analyzing tumor-derived biomarkers through minimally invasive blood tests, clinicians can obtain real-time insights into disease status and treatment response.
• The growing emphasis on personalized medicine and precision oncology continues to support the adoption of liquid biopsy for treatment monitoring. The technology enables the detection of emerging resistance mutations, evaluates treatment efficacy, and facilitates timely modifications to therapy strategies. Such benefits enhance patient management and contribute significantly to the growth of the market.
• The prognosis and recurrence monitoring segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 12.3% over the forecast period. The prognosis and recurrence monitoring segment focuses on evaluating disease progression and identifying the likelihood of cancer recurrence following treatment. Liquid biopsy enables the detection of residual disease and tumor-related biomarkers, providing valuable information regarding patient outcomes and long-term disease management.
• Increasing demand for non-invasive approaches to post-treatment surveillance is driving the adoption of liquid biopsy in this application area. The ability to detect recurrence at an early stage supports timely clinical intervention, improves patient monitoring, and contributes to the expanding utilization of liquid biopsy technologies.
• The treatment selection segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 11.6% over the forecast period. The treatment selection segment involves the use of liquid biopsy to identify actionable genetic alterations and biomarkers that guide personalized therapy decisions. By providing comprehensive molecular insights, liquid biopsy helps clinicians select targeted therapies and immunotherapies that are most suitable for individual patients.
• The growing adoption of precision medicine and companion diagnostics is supporting demand for liquid biopsy-based treatment selection. Enhanced biomarker profiling capabilities enable more informed therapeutic decisions, improving treatment outcomes and driving continued market expansion.

Based on technology, the liquid biopsy market is segmented into multi-gene parallel analysis (NGS), and single gene analysis (PCR microarrays). Multi-gene parallel analysis (NGS) dominates the market with a share of about 75.9% in 2025.

• The multi-gene parallel analysis (NGS) segment accounts for a significant share of the market due to its capability to simultaneously detect multiple genetic alterations, including mutations, insertions, deletions, copy number variations, and gene fusions, from a single sample. This comprehensive profiling capability makes NGS a preferred technology for cancer diagnosis, biomarker identification, and precision medicine applications.
• The increasing demand for comprehensive genomic profiling and personalized treatment approaches is driving the adoption of NGS-based liquid biopsy testing. The technology enables the detection of a broad range of cancer-related biomarkers with high sensitivity and specificity, supporting treatment selection, disease monitoring, and recurrence detection. Continuous advancements in sequencing platforms and data analysis capabilities further contribute to the growth of the liquid biopsy market.
• The single gene analysis segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 11.8% over the forecast period. The single gene analysis (PCR microarrays) segment includes technologies that focus on detecting specific genetic mutations or biomarkers associated with particular diseases. Polymerase chain reaction (PCR)-based methods are widely utilized due to their established clinical utility, rapid turnaround times, and cost-effective testing capabilities.
• The segment continues to play an important role in routine diagnostic applications where targeted biomarker assessment is required. Increasing use of PCR-based liquid biopsy assays for mutation detection, treatment monitoring, and companion diagnostics supports segment growth. Ongoing technological improvements are enhancing analytical performance and expanding the applicability of single-gene testing in clinical settings.

Based on the end use, the liquid biopsy market is segmented into hospitals, research laboratories, clinical laboratories, and other end users. The hospitals segment accounted for the highest market share of 42.2% in 2025.

• The hospitals segment accounted for the highest market share in the market due to the high volume of cancer diagnoses and treatments performed in hospital settings, supported by advanced diagnostic infrastructure and specialized oncology departments. Hospitals are increasingly integrating liquid biopsy into routine clinical workflows to support precision medicine and patient-centered care.
• The growing adoption of minimally invasive diagnostic techniques for cancer detection, treatment selection, and disease monitoring is further supporting segment growth. Hospitals serve as primary centers for comprehensive cancer management, enabling the widespread utilization of liquid biopsy technologies and contributing significantly to overall market expansion.
• The research laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 13.1% over the forecast period. The research laboratories segment comprises academic institutions, biotechnology companies, and dedicated research centers engaged in biomarker discovery and cancer genomics studies. These facilities utilize liquid biopsy technologies to investigate disease mechanisms, validate emerging biomarkers, and develop novel diagnostic approaches.
• Increasing investments in oncology research and precision medicine initiatives are supporting the adoption of liquid biopsy solutions within research environments. Continuous efforts to advance biomarker identification and molecular profiling technologies are contributing to innovation and expanding the future applications of liquid biopsy.
• The clinical laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 12.6% over the forecast period. The clinical laboratories segment includes independent diagnostic laboratories and specialized testing facilities that provide liquid biopsy testing services for healthcare providers. These laboratories play an important role in processing patient samples and generating molecular diagnostic reports to support clinical decision-making.
• Growing demand for genomic testing, companion diagnostics, and personalized treatment planning is driving the utilization of liquid biopsy within clinical laboratories. The expansion of advanced testing capabilities and increasing availability of specialized laboratory services continue to support the growth of this segment.

North America Liquid Biopsy Market

The North America region accounted for 40.8% of the market in 2025. The market in North America is experiencing robust expansion.

• The U.S. market was valued at USD 1.6 billion and USD 1.8 billion in 2022 and 2023, respectively. The market size reached USD 2.3 billion in 2025, growing from USD 2 billion in 2024, and is anticipated to grow at a CAGR of 12% from 2026 to 2035.

• North America holds a significant share of the market, supported by the rising burden of cancer and the increasing adoption of advanced cancer diagnostic technologies across the region. The U.S. represents the largest contributor to regional growth, driven by the growing demand for minimally invasive diagnostic solutions for cancer detection, treatment selection, and disease monitoring. According to the American Cancer Society, more than 2 million new cancer cases and approximately 600,000 cancer-related deaths were projected in the U.S. in 2025, with breast, prostate, lung, and colorectal cancers accounting for a substantial proportion of the disease burden. The increasing prevalence of these cancers continues to accelerate the utilization of liquid biopsy technologies in clinical practice.
• Furthermore, strong awareness among clinicians and patients regarding the benefits of early cancer detection and precision medicine is supporting market expansion across the region. The presence of leading biotechnology and diagnostic companies, coupled with substantial investments in oncology research and favorable government funding initiatives, is fostering continuous innovation in liquid biopsy technologies. Additionally, growing adoption across hospitals, research institutions, and clinical laboratories is enhancing access to advanced molecular testing, further contributing to the growth of the North America market.

Europe Liquid Biopsy Market

Europe market accounted for USD 1.9 Billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The rising burden of cancer across Europe is a major factor driving the growth of the market. The region continues to witness a significant number of cancer cases, generating strong demand for advanced diagnostic technologies that facilitate early disease detection, accurate tumor profiling, and effective patient management. As healthcare systems increasingly emphasize improving cancer outcomes, the adoption of minimally invasive diagnostic approaches such as liquid biopsy is gaining momentum.
• For instance, according to the German Centre for Cancer Registry Data (ZfKD), Germany records more than 500,000 new cancer cases annually, with cancer remaining one of the leading causes of mortality in the country. The high incidence of cancers such as breast, lung, colorectal, and prostate cancer has increased the need for accurate and timely diagnostic solutions that support personalized treatment planning and continuous disease monitoring.
• The growing number of cancer patients across European countries is encouraging healthcare providers to adopt liquid biopsy technologies for a wide range of clinical applications, including early cancer detection, treatment selection, recurrence monitoring, and evaluation of therapeutic response. Furthermore, increasing investments in precision oncology, advancements in genomic testing technologies, supportive healthcare infrastructure, and the growing preference for less invasive diagnostic methods are accelerating the utilization of liquid biopsy, thereby contributing to the expansion of the Europe market.

Asia Pacific Liquid Biopsy Market

The Asia Pacific region is projected to show a lucrative growth of about 6.5% during the forecast period.

• Rising awareness regarding the importance of early disease diagnosis is a significant driver of the Asia Pacific market. Governments, healthcare organizations, and cancer advocacy groups across the region are increasingly promoting cancer screening and early detection initiatives to reduce disease burden and improve survival outcomes. This growing awareness is encouraging both healthcare providers and patients to adopt advanced diagnostic technologies that enable timely and accurate disease identification.
• The increasing acceptance of preventive healthcare and precision medicine is further supporting the adoption of liquid biopsy across Asia Pacific. As patients become more informed about the benefits of minimally invasive testing for cancer detection and monitoring, demand for liquid biopsy solutions continues to rise. Additionally, expanding healthcare infrastructure, improving access to molecular diagnostics, and increasing investments in oncology care are accelerating the utilization of liquid biopsy technologies, thereby driving regional market growth.

Latin America Liquid Biopsy Market 

The Latin America market is experiencing robust growth over the analysis timeframe.

• The Latin America market is being driven by the increasing prevalence of cancer and the growing need for effective, minimally invasive diagnostic solutions. Brazil, the largest healthcare market in the region, continues to experience a significant cancer burden.
• According to Brazil’s National Cancer Institute (INCA), breast cancer remains the most commonly diagnosed cancer among women, with approximately 73,610 new cases annually during 2023–2025 and an incidence rate of 66.54 cases per 100,000 women. The high incidence of cancer is encouraging healthcare providers to adopt advanced diagnostic technologies that support early detection, treatment selection, and disease monitoring.

Middle East and Africa Liquid Biopsy Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• The increasing preference for non-invasive disease diagnosis is a key driver of the Middle East and Africa market. Patients and healthcare providers are increasingly seeking diagnostic approaches that minimize procedural risks, discomfort, and recovery time compared to conventional tissue biopsies.
• Liquid biopsy enables the detection and monitoring of cancer through simple blood samples, supporting early diagnosis and continuous disease assessment. Growing awareness of minimally invasive testing, coupled with improving healthcare infrastructure and expanding access to advanced diagnostics, is driving the adoption of liquid biopsy technologies across the region.

Liquid Biopsy Market Share

• The top five players, Guardant Health, Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., and QIAGEN N.V., collectively account for approximately 55% of the market. Their strong market presence is supported by extensive molecular diagnostics portfolios, advanced liquid biopsy technologies, comprehensive genomic profiling capabilities, broad global distribution networks, and continuous investments in precision oncology and next-generation sequencing solutions.
• Liquid biopsy companies, molecular diagnostics providers, and oncology research institutions are increasingly focusing on technological advancements to enhance the accuracy, sensitivity, and clinical utility of liquid biopsy tests. Key developments include improvements in next-generation sequencing (NGS), digital PCR technologies, multi-biomarker analysis, and advanced bioinformatics platforms for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other cancer-associated biomarkers. Additionally, innovations in automated sample processing, high-throughput testing systems, and artificial intelligence-based data interpretation are improving diagnostic efficiency and clinical decision-making. Continuous investments in advanced diagnostic platforms and precision oncology solutions are supporting broader adoption across hospitals, clinical laboratories, and cancer research centers.
• Market participants, including biotechnology companies, diagnostic laboratories, healthcare providers, and research organizations, are actively strengthening strategic partnerships to expand the applications of liquid biopsy technologies. Collaborations with hospitals, cancer centers, and pharmaceutical companies are enhancing access to advanced molecular testing and supporting the development of companion diagnostics. Furthermore, partnerships with academic institutions and oncology researchers are accelerating innovation in areas such as early cancer detection, treatment monitoring, recurrence assessment, and precision medicine. These initiatives are improving clinical validation, expanding the scope of liquid biopsy applications, and driving the adoption of non-invasive cancer diagnostics across global healthcare systems, thereby contributing to overall market growth.

Liquid Biopsy Market Companies

Few of the prominent players operating in the liquid biopsy industry include:

• ANGLE plc
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• F. Hoffmann-La Roche Ltd.
• Freenome Holdings, Inc.
• GRAIL, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• MDxHealth SA
• Menarini group
• Myriad Genetics, Inc.
• Natera, Inc.
• QIAGEN N.V.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

• Guardant Health, Inc

Guardant Health specializes in precision oncology through advanced liquid biopsy solutions. Its Guardant360 platform enables comprehensive genomic profiling and sensitive detection of actionable cancer biomarkers, supporting personalized treatment decisions and disease monitoring.

• Illumina, Inc

Illumina is a leading provider of next-generation sequencing technologies that power liquid biopsy testing. Its sequencing platforms and oncology-focused assays facilitate highly sensitive ctDNA analysis for cancer detection, biomarker identification, and treatment monitoring.

• QIAGEN N.V.

QIAGEN offers integrated liquid biopsy workflows for the isolation and analysis of circulating biomarkers. Its automated sample preparation solutions and molecular testing technologies support accurate detection of genetic alterations for oncology research and clinical applications.

Liquid Biopsy Industry News

• In September 2025, Myriad Genetics entered a strategic partnership with SOPHiA GENETICS to co-develop a global liquid biopsy companion diagnostic (CDx). The collaboration was centered on MSK-ACCESS powered by SOPHiA DDM, a ctDNA-based test developed with Memorial Sloan Kettering Cancer Center. This hybrid model was aimed at expanding access to precision oncology testing worldwide.
• In April 2025, Guardant Health announced a multi-year global collaboration with Pfizer to integrate its Guardant Infinity smart liquid biopsy platform into Pfizer’s oncology clinical trials. The partnership focused on circulating tumor DNA (ctDNA) monitoring and blood-based epigenomic analyses to advance precision oncology. Additionally, the collaboration extended Guardant’s presence in China through its existing partnership with Adicon Holdings, further strengthening its global footprint in liquid biopsy applications.

The liquid biopsy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

• Consumables
  • Kits and reagents
  • Assay and panels
• Instruments
• Services

Market, By Biomarkers

• Circulating tumor cells (CTC)
• Circulating tumor DNA
• Cell-free DNA
• Extracellular vesicles
• Other biomarkers

Market, By Disease Indication

• Cancer
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Prostate cancer
  • Other cancers
• Non-cancer
  • Non-invasive prenatal testing
  • Organ transplantation
  • Infectious disease testing

Market, By Clinical Application

• Treatment monitoring
• Prognosis and recurrence monitoring
• Treatment selection
• Diagnosis and screening

Market, By Technology

• Multi-gene parallel analysis (NGS)
• Single gene analysis (PCR Microarrays)

Market, By End Use

• Hospitals
• Research Laboratories
• Clinical Laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE